The Congress featured an exhibitor hall with 60 industry partners, comprising IVD companies, pharmaceutical companies, and professional organizations. The following competitors to Werfen’s Hemostasis business were present as exhibitors:
- Stago
- Siemens Healthineers
- Sysmex (including HYPEN BioMed)
- Roche (primarily Pharma with small diagnostic presence)
- Precision Biologic and Affinity Biologicals
- Technoclone
- iLine
Werfen’s booth, located near the front of the exhibition hall, was the largest of any IVD manufacturer in attendance. The new ACL TOP Family 70 Series Hemostasis Testing Systems, including the ACL TOP 970 CL (first ACL TOP system with integrated chemiluminescence), were on display in the US for the first time in US.
Werfen’s Presentation Theater
Werfen also hosted an educational Presentation Theater, “Bridging the Gap: Strategies for Transitioning Patients from Direct Oral Anticoagulants (DOAC) to Unfractionated Heparin (UFH).” Our featured speaker, Dr. Deepa J Arachchillage, from Imperial College London, discussed current heparin monitoring recommendations and practices (UFH and low molecular weight heparin); reviewed the evolution of DOACs and recommendations for laboratory measurement; and outlined potential strategies for monitoring UFH when transitioning patients from an anti-Xa DOAC. The topic was of great interest to the conference attendees; the theater was full to capacity, and many questions were fielded by Dr Deepa following her presentation. A recording is now available in Werfen Academy for the continuing education of our customers.
Relevant Posters:
PB0400 - Validation of a New Automated Chemiluminescent Immunoassay for the detection of anti-platelet factor 4/heparin (PF4/H) IgG antibodies
PB1300 - Clinical performance evaluation of a new system for FXI level determination: sthemO XI on sthemO 301
PB1339 - Non-Severe Hemophilia A: Relationship Among Mutations Factor VIII Levels and Thrombin Generation
PB0272 - Comparability of human and bovine cFVIII assay in mild haemophilia A with FVIII assay discrepancy.
PB0794 - Clinical and Laboratory Profiles in a Series of Acquired Hemophilia Cases. PB1314 - Emicizumab-factor VIII association: impact on hemostasis tests and evaluation of hemostatic efficacy
PB0280 - Effectiveness of emicizumab in hemophilia A: 4th interim analysis of the realworld study EMIIL



